Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$3.65
-0.3%
$3.18
$2.01
$5.64
$242.83M1.521.20 million shs993,961 shs
CervoMed Inc. stock logo
CRVO
CervoMed
$5.87
+3.9%
$7.87
$1.80
$20.63
$51.09M-0.751.34 million shs151,547 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.09
-2.8%
$1.65
$0.60
$3.08
$170.67M1.4391,784 shs351,396 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$18.35
+12.4%
$13.45
$10.80
$18.41
$265.71M-0.0496,094 shs280,697 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.00%+16.06%-5.77%+35.91%+65.43%
CervoMed Inc. stock logo
CRVO
CervoMed
0.00%-5.45%-24.93%-41.39%-63.10%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%-13.23%-8.98%+259.68%+39.38%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%+12.86%+16.99%+35.71%+26.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.669 of 5 stars
3.41.00.00.02.70.00.6
CervoMed Inc. stock logo
CRVO
CervoMed
3.2672 of 5 stars
3.44.00.00.03.31.70.6
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.8797 of 5 stars
3.73.00.00.02.21.70.6
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.992 of 5 stars
0.01.00.04.60.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.80
Moderate Buy$9.88170.55% Upside
CervoMed Inc. stock logo
CRVO
CervoMed
2.89
Moderate Buy$27.63370.61% Upside
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$6.00187.08% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest CRVO, IMAB, CRDF, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$3.50
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/13/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$14.00 ➝ $15.00
5/9/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$680K357.11N/AN/A$1.86 per share1.96
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/A$4.50 per shareN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M43.87N/AN/A$2.47 per share0.85
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,328.54$131.07 per share0.14$9.23 per share1.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)
CervoMed Inc. stock logo
CRVO
CervoMed
-$16.29M-$2.18N/AN/AN/A-200.57%-44.07%-40.65%8/8/2025 (Estimated)
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.16N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)

Latest CRVO, IMAB, CRDF, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/12/2025Q1 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
6.22
6.22
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
9.78
9.78
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
CervoMed Inc. stock logo
CRVO
CervoMed
35.40%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
CervoMed Inc. stock logo
CRVO
CervoMed
48.70 million5.62 millionNot Optionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 millionN/AOptionable

Recent News About These Companies

Inhibrx Biosciences, Inc. (INBX) - Yahoo Finance
Inhibrx Biosciences Inc (INBX) - Investing.com
Inhibrx announces leadership changes as co-founder departs
When the Price of (INBX) Talks, People Listen
Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities
How to Take Advantage of moves in (INBX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$3.65 -0.01 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$3.70 +0.04 (+1.23%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CervoMed stock logo

CervoMed NASDAQ:CRVO

$5.87 +0.22 (+3.89%)
Closing price 04:00 PM Eastern
Extended Trading
$5.85 -0.02 (-0.32%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.09 -0.06 (-2.79%)
Closing price 04:00 PM Eastern
Extended Trading
$2.11 +0.02 (+0.96%)
As of 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$18.35 +2.02 (+12.37%)
Closing price 04:00 PM Eastern
Extended Trading
$18.34 -0.01 (-0.03%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.